RARE · CIK 0001515673 · operating
Ultragenyx Pharmaceutical is a biopharmaceutical company that develops and commercializes therapies for rare and ultra-rare genetic diseases. The company's marketed products include Crysvita (burosumab), a monoclonal antibody for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for Mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for homozygous familial hypercholesterolemia. These products represent the company's primary revenue streams.
The company maintains a substantial pipeline of clinical-stage candidates, with several programs in Phase 3 trials. Notable candidates include UX143 for osteogenesis imperfecta, UX111 (an AAV9 gene therapy for Sanfilippo syndrome type A), DTX401 for glycogen storage disease type Ia, and GTX-102 for Angelman syndrome. Additionally, the company has Phase 2 programs including UX701 for Wilson disease and UX053 for glycogen storage disease type III.
Ultragenyx operates across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. The company maintains partnerships with pharmaceutical firms, academic institutions, and specialized research organizations including Kyowa Kirin, REGENXBIO, Regeneron, and others. As of its latest reporting, the company employed approximately 1,371 full-time employees and is headquartered in Novato, California.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-5.83 | $-5.83 | +7.3% | |
| 2024 | $-6.29 | $-6.29 | +23.8% | |
| 2023 | $-8.25 | $-8.25 | +18.5% | |
| 2022 | $-10.12 | $-10.12 | — | |
| 2021 | — | — | — | |
| 2020 | $-0.37 | $-0.37 | +78.6% | |
| 2019 | $-1.73 | $-1.73 | +0.0% | |
| 2018 | $-1.73 | $-1.73 | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-18 | 0001193125-26-057329 | SEC ↗ |
| 2024-12-31 | 2025-02-19 | 0000950170-25-023312 | SEC ↗ |
| 2023-12-31 | 2024-02-21 | 0000950170-24-017879 | SEC ↗ |
| 2022-12-31 | 2023-02-17 | 0000950170-23-003096 | SEC ↗ |
| 2021-12-31 | 2022-02-15 | 0000950170-22-001284 | SEC ↗ |
| 2020-12-31 | 2021-02-12 | 0001564590-21-005610 | SEC ↗ |
| 2019-12-31 | 2020-02-14 | 0001564590-20-004667 | SEC ↗ |
| 2018-12-31 | 2019-02-20 | 0001564590-19-003324 | SEC ↗ |
| 2017-12-31 | 2018-02-21 | 0001564590-18-002535 | SEC ↗ |
| 2016-12-31 | 2017-02-17 | 0001564590-17-001714 | SEC ↗ |
| 2015-12-31 | 2016-02-26 | 0001564590-16-013430 | SEC ↗ |
| 2014-12-31 | 2015-03-27 | 0001564590-15-002066 | SEC ↗ |